Fluticasone furoate/vilanterol/umeclidinium: Phase III started

GlaxoSmithKline and Theravance began the double-blind, double-dummy, international Phase III FULFIL trial to compare once-daily fluticasone furoate/vilanterol/umeclidinium delivered via GSK’s Ellipta inhaler vs. twice-daily budesonide/formoterol delivered via Turbohaler dry powder inhaler for 24 weeks in about 1,800 patients. About 400 patients will be eligible to continue treatment under a 52-week blinded extension. ...